Telix Pharmaceuticals Participates in Major Conferences
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has announced its participation in two significant global healthcare conferences, highlighting its commitment to advancing patient care through innovative therapies. The UBS Global Healthcare Conference will take place in Palm Beach, followed closely by the Jefferies Global Healthcare Conference in London.
Leadership Engagements at the Conferences
At the UBS conference, Kevin Richardson, the Chief Executive Officer of Precision Medicine, will engage audiences during a fireside chat. This session is scheduled for a popular time that caters to US audiences, allowing for greater participation in discussions surrounding groundbreaking advancements in medical technology.
Meanwhile, Richard Valeix, CEO of Therapeutics, will represent Telix at the Jefferies conference. This platform is particularly valuable for engaging with influential stakeholders in the healthcare sector, discussing the latest developments in therapeutic solutions.
Live Webcasting of Sessions
Both sessions will be broadcast live, ensuring that the insights shared are accessible to a broader audience. Interested parties can easily access the webcasts from Telix's Investor Relations website, fostering transparency and engagement with investors and the public alike.
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals is at the forefront of developing and commercializing innovative therapeutic and diagnostic radiopharmaceuticals, driven by the aim to meet significant unmet medical needs in oncology and rare diseases. With a headquarters in Melbourne, Australia, Telix actively operates in key international markets including the United States, Canada, Europe, and Japan.
Currently, the company is advancing a robust pipeline of products that are in various stages of clinical and commercial development, aiming to transform cancer treatment paradigms and improve patient outcomes.
Further Information and Engagement
Investors and interested stakeholders can engage with Telix via its official website. The site provides comprehensive information about the company, including share prices, important filings with the Australian Securities Exchange, investment presentations, and recent news releases. Telix actively maintains a presence on social media platforms such as LinkedIn, X, and Facebook to keep its community updated.
Contact Information for Investor Relations
If there are inquiries regarding investment or corporate communications, Ms. Kyahn Williamson, Senior Vice President of Investor Relations, is available for contact. Also, for US-specific inquiries, Annie Kasparian serves as the Director of Investor Relations.
Frequently Asked Questions
What are the upcoming conferences Telix will participate in?
Telix is participating in the UBS Global Healthcare Conference and the Jefferies Global Healthcare Conference.
Who will represent Telix at these events?
Kevin Richardson and Richard Valeix will represent Telix at the UBS and Jefferies conferences, respectively.
How can I access the conference sessions?
The conference sessions will be webcast live and can be accessed through Telix's Investor Relations website.
What does Telix Pharmaceuticals specialize in?
Telix focuses on developing therapeutic and diagnostic radiopharmaceuticals aimed at addressing medical needs in oncology and rare diseases.
Where is Telix Pharmaceuticals headquartered?
Telix Pharmaceuticals is headquartered in Melbourne, Australia, with operations in several other countries including the US and Europe.